In Vitro CYP Induction Using Human Hepatocytes View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2014

AUTHORS

Monica Singer , Carlo Sensenhauser , Shannon Dallas

ABSTRACT

Induction potential of compounds towards CYP1A2, 2B6 and 3A4 via the aryl hydrocarbon (AhR), constitutive androstane (CAR), and pregnane X (PXR) nuclear receptors (NRs), respectively, is routinely determined during small molecule drug development. Significant CYP induction can result in therapeutic failure from clinical exposure of a compound outside the therapeutic window, if the respective enzymes are responsible for a significant portion of the drugs overall metabolism and clearance. Co-medications can also be impacted in a similar manner. Additionally, if metabolism via the induced CYP enzyme results in toxic or pharmacologically active compounds being produced, exaggerated pharmacological effects may be seen resulting in direct and/or indirect toxicity. The following chapter will describe methodologies used for determining CYP induction using isolated human hepatocytes, the current gold standard for such in vitro assays. Where appropriate in the chapter recent guidelines will be highlighted by regulatory agencies, such as, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). More... »

PAGES

237-253

Book

TITLE

Optimization in Drug Discovery

ISBN

978-1-62703-741-9
978-1-62703-742-6

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-62703-742-6_14

DOI

http://dx.doi.org/10.1007/978-1-62703-742-6_14

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1030216042


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Arkema (United States)", 
          "id": "https://www.grid.ac/institutes/grid.419047.f", 
          "name": [
            "Drug Safety Sciences, Investigative Toxicology, Janssen Pharmaceutical Research & Development, Spring House, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Singer", 
        "givenName": "Monica", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.497530.c", 
          "name": [
            "Drug Safety Sciences, Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sensenhauser", 
        "givenName": "Carlo", 
        "id": "sg:person.0647536001.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647536001.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.497530.c", 
          "name": [
            "Drug Safety Sciences, Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dallas", 
        "givenName": "Shannon", 
        "id": "sg:person.01213407623.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213407623.24"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.taap.2004.01.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003713737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.112.050583", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007509601"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.23262", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009651386"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10565-011-9208-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011794647", 
          "https://doi.org/10.1007/s10565-011-9208-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10565-011-9208-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011794647", 
          "https://doi.org/10.1007/s10565-011-9208-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/17425255.2010.516251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021609915"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1432-1327.2001.02011.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032491298"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/15376511003690307", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032786762"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/00498250701534893", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033693336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.109.027029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033884114"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.108.020677", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034808977"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.104.003046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035742045"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.tiv.2007.05.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042303343"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.109.026526", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049473624"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014", 
    "datePublishedReg": "2014-01-01", 
    "description": "Induction potential of compounds towards CYP1A2, 2B6 and 3A4 via the aryl hydrocarbon (AhR), constitutive androstane (CAR), and pregnane X (PXR) nuclear receptors (NRs), respectively, is routinely determined during small molecule drug development. Significant CYP induction can result in therapeutic failure from clinical exposure of a compound outside the therapeutic window, if the respective enzymes are responsible for a significant portion of the drugs overall metabolism and clearance. Co-medications can also be impacted in a similar manner. Additionally, if metabolism via the induced CYP enzyme results in toxic or pharmacologically active compounds being produced, exaggerated pharmacological effects may be seen resulting in direct and/or indirect toxicity. The following chapter will describe methodologies used for determining CYP induction using isolated human hepatocytes, the current gold standard for such in vitro assays. Where appropriate in the chapter recent guidelines will be highlighted by regulatory agencies, such as, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).", 
    "editor": [
      {
        "familyName": "Caldwell", 
        "givenName": "Gary W.", 
        "type": "Person"
      }, 
      {
        "familyName": "Yan", 
        "givenName": "Zhengyin", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-62703-742-6_14", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-62703-741-9", 
        "978-1-62703-742-6"
      ], 
      "name": "Optimization in Drug Discovery", 
      "type": "Book"
    }, 
    "name": "In Vitro CYP Induction Using Human Hepatocytes", 
    "pagination": "237-253", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-62703-742-6_14"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "8ff2055d6b809f2adfe3ae47ba374c43959fdb5a7adf7578d86dc0a9d7573c23"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1030216042"
        ]
      }
    ], 
    "publisher": {
      "location": "Totowa, NJ", 
      "name": "Humana Press", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-62703-742-6_14", 
      "https://app.dimensions.ai/details/publication/pub.1030216042"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2019-04-15T23:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8697_00000262.jsonl", 
    "type": "Chapter", 
    "url": "http://link.springer.com/10.1007/978-1-62703-742-6_14"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-62703-742-6_14'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-62703-742-6_14'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-62703-742-6_14'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-62703-742-6_14'


 

This table displays all metadata directly associated to this object as RDF triples.

126 TRIPLES      23 PREDICATES      40 URIs      20 LITERALS      8 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-62703-742-6_14 schema:about anzsrc-for:11
2 anzsrc-for:1115
3 schema:author Na8fc5336d7a049a4bc3d8533dc7ab561
4 schema:citation sg:pub.10.1007/s10565-011-9208-4
5 https://doi.org/10.1002/jps.23262
6 https://doi.org/10.1016/j.taap.2004.01.010
7 https://doi.org/10.1016/j.tiv.2007.05.014
8 https://doi.org/10.1046/j.1432-1327.2001.02011.x
9 https://doi.org/10.1080/00498250701534893
10 https://doi.org/10.1124/dmd.104.003046
11 https://doi.org/10.1124/dmd.108.020677
12 https://doi.org/10.1124/dmd.109.026526
13 https://doi.org/10.1124/dmd.109.027029
14 https://doi.org/10.1124/dmd.112.050583
15 https://doi.org/10.1517/17425255.2010.516251
16 https://doi.org/10.3109/15376511003690307
17 schema:datePublished 2014
18 schema:datePublishedReg 2014-01-01
19 schema:description Induction potential of compounds towards CYP1A2, 2B6 and 3A4 via the aryl hydrocarbon (AhR), constitutive androstane (CAR), and pregnane X (PXR) nuclear receptors (NRs), respectively, is routinely determined during small molecule drug development. Significant CYP induction can result in therapeutic failure from clinical exposure of a compound outside the therapeutic window, if the respective enzymes are responsible for a significant portion of the drugs overall metabolism and clearance. Co-medications can also be impacted in a similar manner. Additionally, if metabolism via the induced CYP enzyme results in toxic or pharmacologically active compounds being produced, exaggerated pharmacological effects may be seen resulting in direct and/or indirect toxicity. The following chapter will describe methodologies used for determining CYP induction using isolated human hepatocytes, the current gold standard for such in vitro assays. Where appropriate in the chapter recent guidelines will be highlighted by regulatory agencies, such as, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
20 schema:editor N7f43deac7de64b2da508a016b1dde782
21 schema:genre chapter
22 schema:inLanguage en
23 schema:isAccessibleForFree false
24 schema:isPartOf Nbe61d472d99c4acf94903f2e4ffc8592
25 schema:name In Vitro CYP Induction Using Human Hepatocytes
26 schema:pagination 237-253
27 schema:productId N3b9a04dfdcaf4f98a41445c2ccfdfee3
28 N42807ef97cd24e2884bda2d56b9708a8
29 Na8638eb86e964d2bb6309396d2d975ca
30 schema:publisher N0f7d3c30f0f847dc808041b8e521ed9f
31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030216042
32 https://doi.org/10.1007/978-1-62703-742-6_14
33 schema:sdDatePublished 2019-04-15T23:52
34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
35 schema:sdPublisher N0d636969d9ee46239216311b21eed7d4
36 schema:url http://link.springer.com/10.1007/978-1-62703-742-6_14
37 sgo:license sg:explorer/license/
38 sgo:sdDataset chapters
39 rdf:type schema:Chapter
40 N0c14d779712d4c019ec322e684e19bfd schema:familyName Caldwell
41 schema:givenName Gary W.
42 rdf:type schema:Person
43 N0d636969d9ee46239216311b21eed7d4 schema:name Springer Nature - SN SciGraph project
44 rdf:type schema:Organization
45 N0f7d3c30f0f847dc808041b8e521ed9f schema:location Totowa, NJ
46 schema:name Humana Press
47 rdf:type schema:Organisation
48 N2160f4c40b4e4430adb644b910a9a28c rdf:first Nf3ce4fa0720842a4902cab1c5fd59009
49 rdf:rest rdf:nil
50 N3b9a04dfdcaf4f98a41445c2ccfdfee3 schema:name dimensions_id
51 schema:value pub.1030216042
52 rdf:type schema:PropertyValue
53 N42807ef97cd24e2884bda2d56b9708a8 schema:name readcube_id
54 schema:value 8ff2055d6b809f2adfe3ae47ba374c43959fdb5a7adf7578d86dc0a9d7573c23
55 rdf:type schema:PropertyValue
56 N4a25ba5878884be49ab0078352f4d97e rdf:first sg:person.0647536001.45
57 rdf:rest Ndbbe9684da32402490d50b6c998e9c73
58 N7f43deac7de64b2da508a016b1dde782 rdf:first N0c14d779712d4c019ec322e684e19bfd
59 rdf:rest N2160f4c40b4e4430adb644b910a9a28c
60 Na8638eb86e964d2bb6309396d2d975ca schema:name doi
61 schema:value 10.1007/978-1-62703-742-6_14
62 rdf:type schema:PropertyValue
63 Na8fc5336d7a049a4bc3d8533dc7ab561 rdf:first Neef940816db3415689a391e3a56b06dc
64 rdf:rest N4a25ba5878884be49ab0078352f4d97e
65 Nbe61d472d99c4acf94903f2e4ffc8592 schema:isbn 978-1-62703-741-9
66 978-1-62703-742-6
67 schema:name Optimization in Drug Discovery
68 rdf:type schema:Book
69 Ndbbe9684da32402490d50b6c998e9c73 rdf:first sg:person.01213407623.24
70 rdf:rest rdf:nil
71 Neef940816db3415689a391e3a56b06dc schema:affiliation https://www.grid.ac/institutes/grid.419047.f
72 schema:familyName Singer
73 schema:givenName Monica
74 rdf:type schema:Person
75 Nf3ce4fa0720842a4902cab1c5fd59009 schema:familyName Yan
76 schema:givenName Zhengyin
77 rdf:type schema:Person
78 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
79 schema:name Medical and Health Sciences
80 rdf:type schema:DefinedTerm
81 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
82 schema:name Pharmacology and Pharmaceutical Sciences
83 rdf:type schema:DefinedTerm
84 sg:person.01213407623.24 schema:affiliation https://www.grid.ac/institutes/grid.497530.c
85 schema:familyName Dallas
86 schema:givenName Shannon
87 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213407623.24
88 rdf:type schema:Person
89 sg:person.0647536001.45 schema:affiliation https://www.grid.ac/institutes/grid.497530.c
90 schema:familyName Sensenhauser
91 schema:givenName Carlo
92 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647536001.45
93 rdf:type schema:Person
94 sg:pub.10.1007/s10565-011-9208-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011794647
95 https://doi.org/10.1007/s10565-011-9208-4
96 rdf:type schema:CreativeWork
97 https://doi.org/10.1002/jps.23262 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009651386
98 rdf:type schema:CreativeWork
99 https://doi.org/10.1016/j.taap.2004.01.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003713737
100 rdf:type schema:CreativeWork
101 https://doi.org/10.1016/j.tiv.2007.05.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042303343
102 rdf:type schema:CreativeWork
103 https://doi.org/10.1046/j.1432-1327.2001.02011.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1032491298
104 rdf:type schema:CreativeWork
105 https://doi.org/10.1080/00498250701534893 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033693336
106 rdf:type schema:CreativeWork
107 https://doi.org/10.1124/dmd.104.003046 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035742045
108 rdf:type schema:CreativeWork
109 https://doi.org/10.1124/dmd.108.020677 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034808977
110 rdf:type schema:CreativeWork
111 https://doi.org/10.1124/dmd.109.026526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049473624
112 rdf:type schema:CreativeWork
113 https://doi.org/10.1124/dmd.109.027029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033884114
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1124/dmd.112.050583 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007509601
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1517/17425255.2010.516251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021609915
118 rdf:type schema:CreativeWork
119 https://doi.org/10.3109/15376511003690307 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032786762
120 rdf:type schema:CreativeWork
121 https://www.grid.ac/institutes/grid.419047.f schema:alternateName Arkema (United States)
122 schema:name Drug Safety Sciences, Investigative Toxicology, Janssen Pharmaceutical Research & Development, Spring House, PA, USA
123 rdf:type schema:Organization
124 https://www.grid.ac/institutes/grid.497530.c schema:alternateName Janssen (United States)
125 schema:name Drug Safety Sciences, Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, PA, USA
126 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...